background: No data are currently available regarding kinetics of human endometrial steroid receptors in stimulated cycles. methods: In 31 patients (age ,39 years) stimulated with gonadotrophins and GnRH antagonists for intrauterine insemination (IUI) an endometrial biopsy was performed on the first day after the end of menstruation and a second biopsy was performed two (Group 0 þ 2, n ¼ 10) or four (Group 0 þ 4, n ¼ 11) days after the first biopsy, or on the day of hCG administration (Group 0 þ hCG, n ¼ 10). Expression of progesterone (PR) and estrogen (ER) receptor was investigated by immunohistochemistry using monoclonal antibodies.
Introduction
Successful implantation depends on the interaction between a normal embryo and a receptive endometrium. In the stimulated cycle endometrial receptivity is compromised as a result of the action of high estradiol (E 2 ) levels, produced by the multiple developing follicles, on steroid endometrial receptors .
The kinetics of steroid endometrial receptors has been investigated both in the natural (Bouchard et al., 1991) and in the stimulated cycle (Papanikolaou et al., 2005) . In the stimulated cycle this was pursued in order to explain the histological advancement of endometrium, present with ovarian stimulation, both in agonist (Marchini et al., 1991; Ubaldi et al., 1997) and in antagonist cycles .
In the study by Papanikolaou et al. (2005) , which evaluated the late follicular phase in antagonist cycles, it was shown that expression of endometrial estrogen receptor (ER) and progesterone receptor (PR) on the day of hCG administration is similar to that present during the first days of the luteal phase. It therefore might be assumed that high E 2 levels during the follicular phase of a stimulated cycle induce premature histological advancement of endometrium through earlier expression of endometrial PR in the follicular phase .
Currently no data exist to describe when endometrial steroid receptor expression is altered in response to the increasing steroid levels during the follicular phase of a stimulated cycle. The aim of the current prospective study is to assess the expression of ER and PR in human endometrium at different days during the follicular phase in stimulated cycles for intrauterine insemination (IUI).
Materials and Methods
Between December 2005 and December 2007, 31 infertile patients were enrolled in this prospective study at the Unit for Human Reproduction of the first Department of Obstetrics and Gynecology, in Aristotle University of Thessaloniki, Greece. All patients gave their informed consent and the research project was accepted by our Institutional Review Board.
Patient population
The inclusion criteria for the present study were: (i) female age ,39 years, (ii) BMI between 18 and 29 kg/m 2 , (iii) normal hysterosalpingography, (iv) E 2 , 80 pg/ml and progesterone level ,1.6 ng/ml on the second day after the onset of menstruation, (v) presence of both ovaries without history of previous operation.
The exclusion criteria were: (i) presence of endometriosis on ultrasound or history of endometriosis, (ii) presence of severe male factor infertility (defined as total motile sperm number ,0.5 Â 10 6 ) (Ben-Chetrit et al., 1995) (iii) presence of endometrial pathology detected by ultrasound. Patients could enter the study only once.
Patient allocation
The concept of this study was to attempt to assess time-related changes in steroid receptor expression during ovarian stimulation for IUI by performing two biopsies on different days during the menstruation-free interval of the follicular phase. The assumption behind this is that no changes of steroid receptor expression can be evaluated during menstruation. Thus, the critical time-point, common to all patients, is the first day after the end of menstruation, in which the first biopsy was taken. This day was defined as 'Day 0'. Using a randomization list at initiation of stimulation, the second biopsy was performed 2 (Group 0 þ 2, n ¼ 10) or 4 days after the first biopsy (Group 0 þ 4, n ¼ 11) or on the day of hCG administration (Group 0 þ hCG, n ¼ 10).
Ovarian stimulation
All patients underwent ovarian stimulation for IUI with a fixed dose of 100 IU of recombinant FSH (rFSH) (follitropin b, NV Organon) starting on the second day after the onset of menstruation and 0.25 mg of GnRH antagonist (Ganirelix, NV Organon). Addition of GnRH antagonist was performed as soon as a follicle with a mean diameter of 14 mm was present, although 5000 IU of hCG (Pregnyl, NV Organon) was administered as soon as a follicle with a mean diameter of 18 mm was present at ultrasound.
Hormonal assessment
Hormonal assessments were performed at initiation of ovarian stimulation, on Day 0 (first biopsy day), on the day of the second biopsy and on the day of hCG administration. Additional blood samples were taken as necessary. Serum LH, E 2 and progesterone levels were measured by means of the automated Immulite 2000 immunoanalyzer (DPC chemiluminescence, Siemens). Intra-assay and inter-assay coefficients of variation were ,4.8 and ,10.7% for LH, ,6.7 and ,9.7% for E 2 and ,9.7 and ,12.2% for progesterone, respectively. All patients underwent ultrasound before the initiation of the ovarian stimulation protocol, on the second day after the onset of menstruation. Ultrasound included follicular and endometrial assessment.
Luteal phase support
Luteal phase was supplemented with vaginal administration of 600 mg of natural micronized progesterone per day (Utrogestan, Faran SA, Greece) in three separate doses, starting 2 days after hCG administration and continuing until 7 weeks of gestation, if pregnancy was achieved.
Endometrial biopsy and histology dating
Endometrial aspiration biopsies were performed using the Wallace endometrial sampler (Suresample, SIMS Portex Limited, Hythe, Kent, UK). Immediately after tissue collection, samples were fixed in neutral buffered formalin 10% (Bouchard et al., 1991) , embedded in paraffin and cut into 3 mm thick sections. Histological evaluation of each sample was performed after staining with hematoxylin and eosin. The samples were classified as early, mid or late proliferative according to the criteria of Noyes et al. (1950) .
Immunohistochemistry
Immunohistochemical detection of hormone receptors was performed with high temperature antigen unmasking in 1 mM EDTA (pH: 8) buffer, which preceded the main procedure. A standardized automated (Nexes, Ventana, Tuscon, AZ, USA), streptavidin -biotin method (I-VIEW Paraffin DAB, Ventana) followed the application of monoclonal antibodies directed against ERa (Novocastra, Newcastle, UK) with a dilution of 1:40, and progesterone receptors (PR-A þ PR-B, Dako, Copenhagen, Denmark) with a dilution of 1:100. Normal cycling endometrium with diffuse 3þ positivity for ER and PR was used as positive control. A negative control for immunostaining was carried out by replacing the primary antibody with nonimmune rabbit serum. The intensity of staining was graded as either absent, weak, moderate or strong (0-3 scale). The immunohistochemical signal was recorded in epithelial cells from the endometrial glands and in stromal cells. In each sample and for each of the two monoclonal antibodies examined, 10 arbitrarily chosen microscopic fields were analyzed and, in each of them, 100 stromal and 100 glandular cells (1000 cells for each type of cell) were observed. A score range between 0 and 3000 was recorded and then expressed as a mean score per 1000 stromal or glandular cells (range: 0 -3) per sample. Differences in ER and PR expression for glands (ERGd and PRGd, respectively) and stromal cells (ERSd and PRSd, respectively) in the groups analyzed were calculated by subtracting the receptor expression present on the second biopsy from that present on the first biopsy. Differences in receptor expression between the days examined is expressed as median difference in intensity of staining. All observations were performed by one of the investigators blinded to the treatment group.
Outcome measures
Primary outcome measure was the difference in expression of ER and PR between the second and the first biopsy among the groups evaluated. Secondary outcome measure was the histological dating of the endometrium assessed using Noyes' criteria (Noyes et al., 1950) .
Statistical analysis
Fisher's exact test was used to analyze nominal variables in the form of frequency tables. For continuous variables, depending on the normality of the values analyzed, Kruskal-Wallis or ANOVA was used for between groups comparison. All tests were two-tailed with a confidence level of 95% (P , 0.05).
No meaningful power analysis was possible owing to the lack of published data regarding receptor kinetics in the stimulated cycle. For this pilot study, it was arbitrarily decided that 10 patients who had completed stimulation and had two biopsies performed should be evaluated in each group. As soon as this was achieved, recruitment was discontinued and at that time, 11 patients had been included in Group 0 þ 4 and 10 patients in the remaining two groups.
Results
Thirty-one women underwent ovarian stimulation with rFSH and GnRH antagonists for IUI and had an endometrial biopsy performed twice, following random allocation in three groups, as described above. Baseline characteristics of the patients participating in the study are shown in Table I . No significant differences were observed between the groups. Table II shows stimulation characteristics in the three study groups. No differences were observed between the three groups (Group 0 þ 2, Group 0 þ 4, Group 0 þ hCG) on the day of the first biopsy (Day 0) for E 2 (P ¼ 0.33), for LH (P ¼ 0.11) and for progesterone (P ¼ 0.09).
Endometrial dating by Noyes' criteria showed that all endometria were in the proliferative phase. On the day of hCG administration in the group 0 þ hCG, 70% of the endometria were shown to be in the late proliferative phase (Table III) .
PR and ER expression were significantly increased in the second as compared with the first biopsy in all the groups analyzed (i.e. Group 0 þ 2, Group 0 þ 4, Goup 0 þ hCG) in both stromal and glandular cells (P ¼ 0.01, Table III ).
The increase of ER expression observed between the second and the first biopsy in glands and stroma was not significantly different between the three groups compared (P ¼ 0.15 and 0.36, respectively) (Table IV) However, the increase in PR expression between the second and the first biopsy was significantly different for glandular cells between the three groups (P ¼ 0.03) (Table IV) with the highest value observed in the Group 0 þ 4. Moreover, the increase in PR expression in stromal cells was significantly different among the groups compared (P ¼ 0.01) with the highest value observed in the Group 0 þ hCG.
Six pregnancies were achieved in the 31 patients analyzed (two ongoing pregnancies, one abortion, one extra-uterine and two biochemical pregnancies). Pregnancies occurred in the study cycle, where the two biopsies were taken.
Discussion
The current study shows that, in the stimulated cycle using rFSH and GnRH antagonist for IUI, PR and ER expression are significantly increased already 2 days after the end of menstruation in both stromal and glandular endometrial cells. This increased expression of steroid endometrial receptors is also present 4 days after the end of menstruation and on the day of hCG administration. ER expression in both glandular and stromal endometrial cells, after an initial increase, does not appear to change significantly during the follicular phase. On the contrary, during the same period of time, following an initial rise, PR expression in glandular and stromal cells continues to increase.
To the best of our knowledge, this is the first study that explores steroid receptor kinetics in the follicular phase of stimulated cycles. In this prospective study all patients underwent the same stimulation protocol using a standard fixed dose of rFSH and endometrial biopsies were taken twice in the same patient, thus minimizing inter-patient variability.
The significantly increased expression of PR in glands and stroma might be explained by the increasing E 2 concentration during the follicular phase in stimulated cycles. Furthermore, the effect on PR expression in stromal cells appears to be caused by differences in the expression at Day 0, instead of differences at the day of hCG. 81.8% (9) 18.2% (2) 0% ( 0% (0) 30% (3) 70% (7 From immunohistochemistry studies, it is known that expression of ER and PR is altered during the normal menstrual cycle. Hence, in the mid follicular period (Days 7 -8), a small proportion of stromal and glandular cells stain positively for PR although staining for ER is more intense and more frequent. During the late follicular and early luteal phase (Days 9-19), the staining for PR increases markedly in glandular cells (Bouchard et al., 1991) . Papanikolaou et al. (2005) explored the late follicular phase in IVF cycles stimulated with rFSH and GnRH antagonists. No secretory changes were noted before the day of hCG administration and all of the endometria in that study were in the late proliferative phase. Papanikolaou et al. (2005) , in agreement with the results presented in the current study, showed a significantly increased expression of PR in stroma and glands on the day of hCG administration. On the other hand Papanikolaou et al. (2005) showed that significant downregulation of ER in the glands was present, which was not the case in the current study. This might be a result of the high doses of FSH used in the study by Papanikolaou et al. (2005) , in which patients were stimulated for IVF as compared with the low FSH doses used in the current study in patients treated for IUI.
In this study, no natural cycle group was included since the aim was to explore steroid receptor kinetics in the follicular phase of stimulated cycles for IUI. The inclusion of a natural cycle control group in a future study will allow the assessment of a potential difference in the kinetics of the endometrial steroid receptors between stimulated and natural cycles. Furthermore, whether the findings of the present study, regarding receptor kinetics, are also true in a stimulated cycle for IVF, where multi-follicular development is the goal, remains also to be evaluated. The relationship between receptor content and pregnancy outcome was not analyzed here because the low number of patients studied precluded such an analysis from reaching meaningful conclusions.
In conclusion, in stimulated cycles for IUI, ER expression in both glandular and stromal endometrial cells, after an initial increase, does not appear to change significantly during the follicular phase. On the contrary, during the same period of time, following an initial rise, PR expression in glandular and stromal cells continues to increase.
